Kevin Haney, MD
Family Medicine · Delaware, OHNPI 1235193194
Payments from drug & device makers
Across 363 payments — averaging $80.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$24K
- AbbVie$738
- AstraZeneca$711
- Novo Nordisk$666
- Pfizer$466
- Lilly USA, LLC$345
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,11018%
- Education$14,41449%
- Other$9,60033%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 5 | $24,000 |
| AbbVie(2 entities) | 65 | $738 |
| AstraZeneca | 37 | $711 |
| Novo Nordisk | 51 | $666 |
| Pfizer | 30 | $466 |
| Lilly USA, LLC | 26 | $345 |
| GSK | 17 | $239 |
| Boehringer Ingelheim | 18 | $184 |
| Sanofi-aventis U.S. LLC | 13 | $173 |
| Bayer | 7 | $140 |
| Exact Sciences | 6 | $131 |
| Medtronic | 2 | $123 |
| Biohaven Pharmaceutical Holding Company Ltd. | 16 | $120 |
| Astellas Pharma US Inc | 7 | $117 |
| Sanofi Pasteur Inc. | 5 | $106 |
| Amgen | 6 | $96 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $86 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $75 |
| Xeris Pharmaceuticals, Inc. | 4 | $69 |
| Amarin Pharma, Inc. | 4 | $69 |
| Merck | 5 | $67 |
| Phathom Pharmaceuticals, Inc. | 3 | $60 |
| Cranial Technologies, Inc | 3 | $56 |
| Johnson & Johnson | 3 | $40 |
| Abbott | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 3 | $37 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| 180 Medical, Inc. | 1 | $26 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Genentech USA, Inc. | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Novartis | 1 | $18 |
| Aimmune Therapeutics, Inc. | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Asahi Intecc USA, Inc. | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$29,124 in reported general payments places this provider in the 95th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 153 | $163,539 |
| AustedoDeutetrabenazine | 19 | $121,435 |
| TrulicityDulaglutide | 77 | $100,772 |
| EliquisApixaban | 104 | $94,324 |
| JardianceEmpagliflozin | 99 | $82,178 |
| OzempicSemaglutide | 62 | $73,002 |
| XareltoRivaroxaban | 48 | $59,967 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $48,601 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 31 | $27,776 |
| FarxigaDapagliflozin Propanediol | 24 | $25,637 |
| Xigduo XrDapaglifloz Propaned/Metformin | 24 | $25,373 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $12,475 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 15 | $12,056 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $11,902 |
| TrintellixVortioxetine Hydrobromide | 17 | $11,090 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $345 | $264,310230 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $37 | $121,43519 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $184 | $116,984144 claims |
| PfizerEliquis | $466 | $94,324104 claims |
| Novo NordiskOzempic | $666 | $73,00262 claims |
| Johnson & JohnsonXarelto | $40 | $59,96748 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $239 | $56,66592 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $711 | $38,11242 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $75 | $11,09017 claims |
| Astellas Pharma US IncMyrbetriq | $117 | $10,90916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Delaware
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.